An Early Phase 1 interventional study of Oxytocin and Placebo in Eating Behavior, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-08.
Sponsored by Massachusetts General Hospital · Early Phase 1, Interventional, and Other
Exciting advances have led to the concept that hormones can modulate appetite and food intake. Oxytocin is a peptide hormone that is released in regions throughout the brain, including areas involved in food motivation. Animal studies suggest that oxytocin may reduce food intake. The effects of oxytocin administration on eating behavior in humans, which could have important implications in eating-related disorders ranging from obesity to anorexia nervosa, have not been investigated. This double-blind placebo-controlled cross-over study of single-dose oxytocin administration investigates whether:
Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intranasal oxytocin
Drug: Oxytocin
Intranasal placebo
Drug: Placebo
Intranasal oxytocin 24 IU single-dose administration
Also known as: Syntocinon (Novartis)
Intranasal Placebo single-dose administration
Caloric intake
Time frame: +60 minutes after drug/placebo
Appetite
Assessed using a Visual Analogue Scale
Time frame: +55 (fasting) and +90 minutes (post-prandial) after drug/placebo
Resting energy expenditure
Assessed using metabolic cart
Time frame: +30 minutes after drug/placebo
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital